The Economic Times

Anupam Rasayan completes Bliss GVS deal, targets Rs 4,000-crore integrated platform

Anupam Rasayan India Limited has finalised its acquisition of a controlling interest in Bliss GVS Pharma, marking a strategic expansion into finished dosage formulations. This acquisition strengthens Anupam Rasayan's pharmaceutical portfolio, bolstered by Bliss GVS Pharma's extensive array of over 150 brands across several therapeutic segments, while also offering valuable growth avenues through their current manufacturing infrastructure.